α1 Antitrypsin deficiency: current best practice in testing and augmentation therapy.

doi:10.1177/1753465814542243

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

α1 Antitrypsin deficiency: current best practice in testing and augmentation therapy.

Therapeutic advances in respiratory disease - 1 Oct 2014

Campos Michael A, Lascano Jorge

Abstract excerpt

α1 Antitrypsin deficiency (AATD) increases the risk of chronic obstructive pulmonary disease (COPD), liver disease and other conditions. Although it is not a rare disease, it is a condition rarely diagnosed because of unawareness by most healthcare providers who manage subjects at risk. Testing recommendations have been published and strongly suggest testing all subjects with confirmed COPD, cryptogenic liver...

Topics

Disease Progression
Emphysema
Genotype
Humans
Liver Cirrhosis
Phenotype
Precision Medicine
Pulmonary Disease, Chronic Obstructive
Tomography, X-Ray Computed
alpha 1-Antitrypsin
alpha 1-Antitrypsin Deficiency

Source

Open in PubMed

Identifiers

PMID: 25013223
DOI: 10.1177/1753465814542243

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics